第一作者:
Susan,O'Brien
第一单位:
From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.
作者:
医学主题词
抗肿瘤药(Antineoplastic Agents);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);人类(Humans);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);预后(Prognosis);蛋白激酶抑制剂(Protein Kinase Inhibitors)
DOI
10.6004/jnccn.2013.0157
PMID
24225967
发布时间
2021-10-21
基金项目
P30 CA006973/CA/NCI NIH HHS/United States
P30 CA016672/CA/NCI NIH HHS/United States
- 浏览30
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



